Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Century Therapeutics (IPSC) EBT (2022 - 2025)

Century Therapeutics (IPSC) has disclosed EBT for 4 consecutive years, with -$19.2 million as the latest value for Q4 2025.

  • Quarterly EBT fell 121.26% to -$19.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$9.6 million through Dec 2025, down 241150.0% year-over-year, with the annual reading at -$9.6 million for FY2025, 193060.0% down from the prior year.
  • EBT for Q4 2025 was -$19.2 million at Century Therapeutics, up from -$34.4 million in the prior quarter.
  • The five-year high for EBT was $90.5 million in Q4 2024, with the low at -$40.3 million in Q4 2023.
  • Average EBT over 4 years is -$17.2 million, with a median of -$31.2 million recorded in 2024.
  • Peak annual rise in EBT hit 372.83% in 2025, while the deepest fall reached 121.26% in 2025.
  • Over 4 years, EBT stood at -$31.6 million in 2022, then decreased by 27.23% to -$40.3 million in 2023, then surged by 324.71% to $90.5 million in 2024, then tumbled by 121.26% to -$19.2 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$19.2 million, -$34.4 million, and -$32.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.